06 March 2020 – Funded vaccine research and development through HHS and NIAD

This item is sourced from COVID-19 Policy Watch co-ordinated by Policy. We are in the process of gathering further information and aligning taxonomies for these items.

Type of Intervention: Research
Sectors Involved:
Level of Jurisdiction: Federal
Lead People/Agency:

Overview: The U.S. Congress provided more than $2 billion for the Biomedical Advanced Research and Development Authority (BARDA) in the Department of Health and Human Services for the research and development of vaccines, therapeutics, and diagnostics, as part of phase 1 legislation.

The legislation also included $300 million in contingency funding for the purchase of vaccines, therapeutics, and diagnostics if necessary as deemed by the Secretary of Health and Human Services, and $836 million for research into vaccines, therapies, and diagnostics through the National Institute of Allergy and Infectious Diseases (NIAID).
Full details here: https://www.kff.org/global-health-policy/issue-brief/the-u-s-response-to-coronavirus-summary-of-the-coronavirus-preparedness-and-response-supplemental-appropriations-act-2020/